Status:
UNKNOWN
Discontinuation of Postmenopausal Hormone Therapy: Impact on the Cardiovascular System and Quality of Life
Lead Sponsor:
Hanna Savolainen-Peltonen
Collaborating Sponsors:
University of Southern California
Conditions:
Menopause
Atherosclerosis
Eligibility:
FEMALE
Up to 60 years
Phase:
PHASE4
Brief Summary
Although the impact of postmenopausal hormone therapy (HT) on cardiovascular disease risk has been studied in several large randomized trials, little is known about the acute cardiovascular consequenc...
Eligibility Criteria
Inclusion
- healthy postmenopausal women
- age ≤ 60 years
- has used postmenopausal hormone therapy for at least 3 years
Exclusion
- any clinically significant disease
- use of regular medication
- history of cardiovascular events
- history of smoking
- body mass index over 30 kg/m2
- thickness of endometrium over 6 millimeters
Key Trial Info
Start Date :
February 19 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04050592
Start Date
February 19 2020
End Date
December 1 2022
Last Update
February 15 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HUS Women's Hospital
Helsinki, Finland, 00290